In late 2002, cases of life-threatening respiratory disease with no identifiable cause were reported from Guangdong Province, China, and they were followed by reports from other countries. The syndrome was designated "severe acute respiratory syndrome" (SARS). Investigators used a combination of traditional methods and molecular techniques to identitify the unknown pathogen. Researches showed that SARS is caused by a new coronavirus, never detected before and which is not related to any of the known coronaviruses.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2298/mpns0502043k | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impaired Hepatitis B and COVID-19 vaccination responses show strong concordance in hemodialysis patients with end stage renal disease.
Eur J Med Res
January 2025
Department of Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
Background: Patients with end stage renal disease (ESRD) undergoing hemodialysis are at increased risk for infection and impaired vaccination responses. We analyzed overlap and influencing factors of vaccination responses against severe acute respiratory syndrome corona virus disease 2 (SARS-CoV-2) and Hepatitis B virus (HBV).
Methods: SARS-CoV-2 and HBV vaccination response was assessed in a cohort of German ESRD hemodialysis patients.
Thiol-Reactive or Redox-Active: Revising a Repurposing Screen Led to a New Invalidation Pipeline and Identified a True Noncovalent Inhibitor Against Papain-like Protease from SARS-CoV-2.
ACS Pharmacol Transl Sci
January 2025
Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Discovery Research ScreeningPort, Schnackenburgallee 114, 22525 Hamburg, Germany.
The SARS-CoV-2 papain-like protease PLpro has multiple roles in the viral replication cycle, related to both its polypeptide cleavage function and its ability to antagonize the host immune response. Targeting the PLpro function is recognized as a promising mechanism to modulate viral replication, while supporting host immune responses. However, the development of PLpro-specific inhibitors remains challenging.
View Article and Find Full Text PDFIncidence of seroma and postoperative complications after breast surgery before and during the Covid-19 pandemic: results from a retrospective multicenter analysis.
BMC Cancer
January 2025
Department of Gynecology with Breast Center, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Charité Universitätsmedizin Berlin, Berlin, Germany.
Background: In recent years, there has been a growing number of case reports documenting delayed seroma in patients with a history of breast surgery and reconstruction. The occurrence of these seromas has been associated with prior SARS-CoV-2 infection or SARS-CoV-2 vaccination. So far, there are few systematic analyses on postoperative complications in breast surgery since the emergence of the SARS-CoV-2 pandemic.
View Article and Find Full Text PDFEcofriendly spectrophotometric methods for simultaneous determination of remdesivir and moxifloxacin hydrochloride as co administered drugs in corona virus treatment.
Sci Rep
January 2025
Department of Medicinal Chemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt.
Remdesivir and moxifloxacin hydrochloride are among the most frequently co-administered drugs used for COVID-19 treatment. The current work aims to evaluate green spectrophotometric methodologies for estimating remdesivir and moxifloxacin hydrochloride in different matrices for the first time. The proposed approaches were absorbance subtraction, extended ratio subtraction and amplitude modulation methods.
View Article and Find Full Text PDFAcute gastrointestinal and post-acute COVID-19 gastrointestinal syndrome assessment on the Gastrointestinal Symptom Rating Scale scoring system: A questionnaire-based survey.
J Family Med Prim Care
December 2024
Nursing Tutor, Vardhman Mahaveer Nursing Medical College, New Delhi, India.
Background: Post-acute coronavirus disease 2019 (COVID-19) syndrome (PACS) is the persistence of sequel of acute SARS-COV-2 infection. Persistent/acquired gastrointestinal symptoms (GI-PACS) include loss of appetite, nausea, weight loss, abdominal pain, heartburn, dysphagia, altered bowel motility, dyspepsia, and irritable bowel syndrome. The study aimed to assess the short- and long-term GI-PACS syndrome on the GSRS scale.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!